Benzimidazolylpropionic acid | 884504-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Benzimidazolylpropionic acid
• 英文别名: 2-(1H-benzimidazol-2-yl)propanoic acid
• CAS: 884504-57-8
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: ODWFHOJKRNDFFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Benzimidazolylpropionic acid 在 溴 、 potassium acetate 作用下， 以 水 为溶剂， 生成 2-(6-bromo-1H-benzimidazol-2-yl)propanoic acid
  参考文献：
  名称：

  Yadava, Virendra Singh; Yadav, Vijay Shankar, Heterocyclic Communications, 2008, vol. 14, # 5, p. 319 - 322

  摘要：

  DOI：

文献信息

• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
• New amino-alkyl-amide derivatives as CCR3 receptor ligands
  申请人：PAPPNE BEHR Agnes

  公开号：US20080287434A1

  公开（公告）日：2008-11-20

  The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.

  本发明涉及一种通式（I）所定义的化合物，其对治疗患者中CCR3受体在病理发展中发挥作用的疾病有用，并且包含这种化合物的制药制剂。本发明还涉及一种制备通式（I）所定义的化合物的方法，以及在制备中有用的中间体。
• Proline bis-amide orexin receptor antagonists
  申请人：Bergman Jeffrey M.

  公开号：US20090118200A1

  公开（公告）日：2009-05-07

  The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及丙氨酸双酰胺化合物，其为促进素受体拮抗剂，可用于治疗或预防涉及促进素受体的神经和精神障碍和疾病。本发明还涉及包含这些化合物的制药组合物以及利用这些化合物和组合物预防或治疗涉及促进素受体的这些疾病的用途。
• PHARMACEUTICAL COMPOSITION AND METHOD
  申请人：Slade Rachel M.

  公开号：US20090155903A1

  公开（公告）日：2009-06-18

  The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ 42 -related diseases and disorders.

  该发明提供了化合物、制药组合物和方法，用于治疗和预防神经退行性疾病和其他与Aβ42相关的疾病和障碍。
• VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0869787A1

  公开（公告）日：1998-10-14